Recognizing
Excess Visceral Abdominal Fat

Excess visceral abdominal fat is fat located deep within the abdomen. This is also known as central adiposity.1,2

  • It is a deep layer of hard-feeling fat that surrounds the abdominal organs.1,2
  • It differs from regular fat (subcutaneous fat), which is doughy, easy to pinch, and found just beneath the skin.1,2

Excess visceral abdominal fat is a hard fat that feels firmer than regular fat and may be hard to manage with diet and exercise alone.3,4

Excess visceral abdominal fat can be difficult for patients to accurately describe and often presents as general weight gain or obesity. Talk to your patients about what they’re feeling and conduct a physical exam to determine if they may be a candidate for treatment with EGRIFTA SV®.

3 easy steps to check for excess visceral abdominal fat include5,6:

  • Palpating the abdomen for firmness
  • Measuring hip and waist circumference
  • Calculating waist-to-hip radio (waist circumference/hip circumference)

Indicators of Excess Visceral Abdominal Fat*:

*Based on inclusion criteria in clinical trials for tesamorelin for injection.

Confronting the Challenge of Excess Visceral Abdominal Fat

The pathogenesis of increased excess visceral abdominal fat in patients with HIV appears to be due to multiple factors, including3,5,7:
Excess visceral abdominal fat in people with HIV may be associated with a variety of negative health outcomes and elevated mortality risk.4,7,8
Patients who are treated for HIV might have lipohypertrophy, including excess visceral abdominal fat, i.e. the build up of excess fat around the stomach and other organs in the abdomen area.

Learn more about the only FDA approved treatment that targets excess visceral abdominal fat, a different type of fat.

References: 1. Carleir RY, de Truchis P, Ronze S, et al. MRI of intra-abdominal fat and HIV-associated lipodystrophy: a case review. J Radiol. 2007;88:947-955. 2. Sethi JK, Vidal-Pulg AJ. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007;48:1253-1262. 3. Falutz J. Management of fat accumulation in patients with HIV infection. Curr HIV/AIDS Rep. 2011:8(3):200-208. 4. Carter M, Hughson G. Lipodystrophy. http://www.aidsmap.com/lipodystrophy/page/1045065/. Accessed April 28, 2017. 5. National Institutes of Health: AIDS info: guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. April 8, 2015. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 28, 2017. 6. Shuster A, Patlas M, Pinthus JH, et al. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012;85(1009):1-10. 7. Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab. 2008;93(8):2937-2945. 8. Scherzer R, Heymsfield SB, Lee D, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS. 2011;25(11):1405-1414. 9. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects in randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG study A5224s. Clin Infect Dis. 2011;53(2):185-196. 10. Chow D, Day L, Souza S, et al. Metabolic complications of HIV therapy. IAPAC Mon. 2006;12(9):302-317.